LGALS3 and idiopathic pulmonary fibrosis: Inhaled therapy with TD139 (a novel and potent small-molecule inhibitor of Galectin (Gal)-3 a profibrotic β-galactoside-binding lectin that plays a key role in the pathogenesis of IPF and IPF exacerbations) has been recently tested in IPF patients with encouraging results [23].